FTRE vs ICLR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: ICLR is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FTRE and ICLR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FTRE and ICLR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Fortrea Holdings is a global contract research organization (CRO) that runs clinical trials on behalf of pharmaceutical, biotech and medical device companies. It was separated from Labcorp in July 2023 and largely traces back to Covance, which Labcorp bought in 2015. Fortrea operates in roughly 90 countries and has three main pieces of business. Clinical pharmacology covers early-stage Phase I studies run in its own clinical units, where healthy volunteers or patients receive a drug for the first time. Full-service clinical development means managing Phase II to IV trials end to end, from site selection and patient recruitment through data management and regulatory submission. Functional service provision, or FSP, supplies dedicated staff who work inside a sponsor's own trial operations. Revenue comes from multi-year contracts, which is why backlog (about ~$7.8 billion at June 30, 2026, or nearly three years of revenue) is the number analysts watch most closely.

Full FTRE guide

ICON plc (NASDAQ: ICLR) is a Dublin-headquartered contract research organization that provides outsourced clinical development services to pharmaceutical, biotechnology, medical device, and government clients. As of March 2026 it had roughly 40,350 employees across about 97 locations in 55 countries, and it manages studies spanning compound selection through Phase I to Phase IV trials. Revenue is booked against a large backlog, so bookings and book-to-bill ratios are watched as closely as reported sales.

Full ICLR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• FTRE drivers: Bookings recovery feeding the backlog; Cost structure after the Labcorp separation.
• ICLR drivers: Backlog and bookings momentum; Structural CRO outsourcing growth.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Revenue is still declining year over year, so the recovery case rests on bookings converting to growth rather than on results already delivered. For ICLR, iCON faces cyclical risk from pharmaceutical reprioritization, trial cancellations, and swings in biotech funding, all of which can slow bookings conversion.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick FTRE if you believe its drivers more; ICLR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FTRE and ICLR guides.

FTRE. On GAAP numbers Fortrea is still loss-making (a ~$13 million net loss in Q2 2026 and roughly ~$85 million over the trailing twelve months), so the stock is usually valued on adjusted earnings, where the forward P/E is about ~24x, and on enterprise value. At roughly ~$3.1 billion, enterprise value is about ~14 to ~15x the midpoint of 2026 adjusted EBITDA guidance and a little over 1x sales. That multiple is not cheap for a company whose revenue is shrinking, which means the current price leans on margin expansion and a return to growth in 2027. For comparison, the stock traded near ~$850 to ~$880 million of market cap in late March and early April 2026, so most of the rerating has come from the Q2 beat and guidance raise. Post-earnings analyst targets in July 2026 ranged from roughly ~$20 (Deutsche Bank) to ~$26 (Truist), and the stock now sits near the upper half of that range. Fortrea's next quarterly report, for Q3 2026, is the next test of whether bookings are turning into revenue.

ICLR. ICON reiterated full-year 2026 guidance with its second-quarter results, and analysts sit near the middle of it at about $10.57 of adjusted EPS, then about $11.78 for 2027. The trailing GAAP multiple is not meaningful because reported profit has been squeezed to about $27 million over twelve months, so the market is pricing the stock at roughly 14.7 times forward earnings. Third-quarter results on October 27, 2026 are the next read on whether strong bookings start turning into revenue growth.

Headline figures (approximate, October 2026): FTRE shows revenue (ttm) ~$2.68 billion, 2026 revenue guidance ~$2.62 to ~$2.69 billion, 2026 adjusted ebitda guidance ~$205 to ~$220 million, market cap ~$2.2 billion (share price ~$22.75); ICLR shows market cap ~$13.3B, revenue (ttm) ~$8.3B (+~1.2% y/y in Q2 2026), q2 2026 revenue ~$2.06B, q2 2026 adjusted eps ~$2.56 vs ~$2.52 expected.

FTRE and ICLR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FTRE and ICLR exposure against your real portfolio. It is not an investment adviser.